Sika Undertakes Structural Adjustments Amid Weak Markets
On October 24, 2025, Sika announced Q3 operating results and ongoing structural adjustments in China and other weak markets. The company expects one-time costs of CHF 80–100 million in 2025, including up to 1,500 layoffs.
Despite a double-digit decline in China’s construction business, sales for the first nine months grew 1.1% in local currency, with 3% growth outside China.
The EBITDA margin improved to 19.2%, supported by lower input costs and successful MBCC integration, even though volume declines in China reduced EBITDA by approximately 50 basis points. Overall, Sika’s EBITDA for the first nine months was CHF 1.64 billion, slightly lower than last year.
You May Interested In
High Quality β-Nicotinamide adenine dinucleotide CAS 53-84-9 NADwith ready stock and best price
$3/UNIT FOB
2026-10-19
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
TSMC, Samsung, and SK Hynix Scramble for Electronic-Grade Hydrofluoric Acid as High-End Supply Tightens; Some Suppliers Raise Prices by 30% This Year
-
“Amputation or Strategic Retreat?”: Shell’s Six-Year Chemical Losses and the Quiet Unwinding of an Empire
-
Tinci Materials Calls Off 2.65 Billion Yuan Project as Electrolyte Giant Shifts Strategy
-
“The 40-Year Ethylene Giant Collapses”: ExxonMobil’s Premature Shutdown Is Not Just Scotland’s Tragedy—It’s the Twilight Elegy of European Industrial Civilization
-
Eastern Shenghong Projects First-Half Profit of 5 Billion Yuan – A Collective Turnaround for the Four Major Private Refiners? Is the Chemical Sector Rebounding?
-
U.S.-Iran Détente Triggers Oil Price Plunge, Energy and Chemical Sectors Tumble
-
Sulfur Price Hits 7,633 CNY/Ton, Up Nearly Sixfold in a Year and a Half; Domestic Refining Giants Halt New Orders Due to Tight Supply
-
Indian Immunologicals Pushes Back on “Fake Vaccine” Claims Amid Global Supply Chain Scrutiny
-
Obesity Drugs Become Pharma’s Most Powerful Growth Engine
-
Substandard Drug Findings Expose Deep Structural Gaps in Medicine Quality Control
Recommend Reading
-
![What Can $3.4 Billion Buy? Shin-Etsu Chemical’s Answer: Upstream Control of PVC]()
What Can $3.4 Billion Buy? Shin-Etsu Chemical’s Answer: Upstream Control of PVC
-
![Behind Japan's Tungsten Hexafluoride Crisis: Can China's Electronic Specialty Gases Seize a New Opportunity?]()
Behind Japan's Tungsten Hexafluoride Crisis: Can China's Electronic Specialty Gases Seize a New Opportunity?
-
![Lianolong Bets Big on Electronic Adhesives with $50M Strategic Stake in Sidofu]()
Lianolong Bets Big on Electronic Adhesives with $50M Strategic Stake in Sidofu
-
![Sichuan Unveils Revised List of 14 Qualified Chemical Parks in Major Industrial Realignment]()
Sichuan Unveils Revised List of 14 Qualified Chemical Parks in Major Industrial Realignment
-
![China’s Chemical Time Bomb Just Got a Legal Fuse: The New Law That Could Save Thousands of Lives]()
China’s Chemical Time Bomb Just Got a Legal Fuse: The New Law That Could Save Thousands of Lives
-
![Ammonia Chemical Formula: NH3 Structure & Properties]()
Ammonia Chemical Formula: NH3 Structure & Properties
-
![Benzyl Alcohol: Uses in Cosmetics, Preservative Efficacy, and Safety]()
Benzyl Alcohol: Uses in Cosmetics, Preservative Efficacy, and Safety
-
![China's EVA Market Prices Surge Significantly]()
China's EVA Market Prices Surge Significantly
-
![Supply Contraction Keeps Raw Materials Firm; PP Market Prices Remain High and Continue to Rise]()
Supply Contraction Keeps Raw Materials Firm; PP Market Prices Remain High and Continue to Rise
-
![Supply and Demand Dynamics Continue, Formic Acid Prices Rise]()
Supply and Demand Dynamics Continue, Formic Acid Prices Rise
